TNFRSF17 and Miyoshi myopathy: Data from clinical trials have demonstrated that patients with relapsed and/or refractory MM can achieve objective responses in short-term safety and efficacy by applying anti-BCMA (B cell maturation antigen) CAR-T cells [49] (Table 1).